Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Stockwatch: Teva And Mylan Hit Terminal Velocity

Executive Summary

Another social media jump on the drug pricing bandwagon by Hillary Clinton directed at Mylan's EpiPen pricing policy temporarily sank most life science stock prices last week. Fortunately, the lasting impact should be limited to Teva and Mylan.


Related Content

PTAB Knocks Out Two Copaxone 40 mg Patents
EpiPen's Swollen Price May Trigger Patient Assistance Program Probes


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst